Targets › B4GALNT1
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Mar 2027.
Involved in the biosynthesis of gangliosides GM2, GD2, GT2 and GA2 from GM3, GD3, GT3 and GA3, respectively. (UniProt, Q00973)
Open in Phaseline: the race on B4GALNT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Prof. Dr. Dr. Birgit Burkhardt | Dinutuximab beta Anti-GD2 monoclonal antibody | B4GALNT1 | Phase 1 | High-risk GD2 Positive Ewing Sarkoma | Mar 2027 |
| University Hospital Southampton NHS Foundation Trust | Ch14.18/CHO Anti-GD2 monoclonal antibody | B4GALNT1 | Phase 1 | Neuroblastoma | – |
Neuroblastoma (1) High-risk GD2 Positive Ewing Sarkoma (1)
antibody (2)
University Hospital Southampton NHS Foundation Trust (1) Prof. Dr. Dr. Birgit Burkhardt (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.